Show simple item record

dc.contributor.authorSmalley, KSM
dc.contributor.authorEisen, TG
dc.date.accessioned2018-09-18T14:42:10Z
dc.date.issued2002-04-01
dc.identifier4
dc.identifier.citationINTERNATIONAL JOURNAL OF CANCER, 2002, 98 pp. 514 - 522
dc.identifier.issn0020-7136
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2796
dc.identifier.doi10.1002/ijc.10213
dc.description.abstractNovel classes of drug that interfere with the signalling of the small G-protein Ras, the so-called Ras antagonists, are showing much promise as novel anti-cancer agents. In this study, we demonstrate that the novel Ras antagonist farnesylthiosalicylic acid (FTS) inhibits the growth of Colo 853 melanoma cells through a combination of cytostatic and pro-apoptotic effects. Furthermore, these phenomena are seen under conditions of cell attachment and in the presence of serum. Treatment of Colo 853 cells with FTS led to time-dependent inhibition of constitutive Akt, retinoblastoma protein (pRB) and ERK activity, with a concurrent loss of Akt expression. Inhibition of Akt and ERK activity induces apoptosis in other human cancer cell lines. Here it is demonstrated that inhibition of Akt, or ERK and Akt in combination, leads to cell cycle arrest but not apoptosis in melanoma cells. FTS treatment was also found to upregulate activity of the stress-activated p38 MAP kinase. Inhibition of p38 MAP kinase, using the selective inhibitor SB 203580, followed by FTS treatment, significantly increased the proportion of apoptotic cells after 72 hr, possibly suggesting a modulatory role for p38 MAP kinase in FTS-induced melanoma cell apoptosis. (C) 2002 Wiley-Liss, Inc.
dc.format.extent514 - 522
dc.languageeng
dc.language.isoeng
dc.titleFarnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/ijc.10213
rioxxterms.licenseref.startdate2002-04-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfINTERNATIONAL JOURNAL OF CANCER
pubs.notesresearcherid-numbers: Smalley, Keiran/A-1320-2007 orcid-numbers: Smalley, Keiran/0000-0002-4121-8335 unique-id: ISI:000174171800005
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume98
pubs.embargo.termsNot known
dc.contributor.icrauthorEisen, Timen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record